Ipilimumab - Biologic Drug Details

Summary for ipilimumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ipilimumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ipilimumab

Recent Clinical Trials for ipilimumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jun Zhang, MD, PhD	Phase 2
AstraZeneca	Phase 3
Neonc Technologies, Inc.	Phase 1/Phase 2

See all ipilimumab clinical trials

Recent Litigation for ipilimumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Bristol-Myers Squibb Co. v. AstraZeneca Pharmaceuticals LP	2023-01-23
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.	2022-03-17

See all ipilimumab litigation

PTAB Litigation

Petitioner	Date
Replimune Limited et al.	2022-11-02

See all ipilimumab litigation

Pharmacology for ipilimumab

Mechanism of Action	CTLA-4-directed Antibody Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CTLA-4-directed Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ipilimumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ipilimumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ipilimumab Derived from Patent Text Search

No patents found based on company disclosures